Document is current
Any future updates will be listed below
-
Authors
Bloem, M.N. https://orcid.org/0000-0001-9152-9505
Baaleman, D.F. https://orcid.org/0000-0002-0163-9354
Koppen, I.J.N. https://orcid.org/0000-0002-1856-0968
Bijlsma, M.W. https://orcid.org/0000-0003-3246-5083
Vlieger, A.M. https://orcid.org/0000-0002-3869-2896
Goede, J. https://orcid.org/0000-0003-2935-3910
Plötz, F.B. https://orcid.org/0000-0003-3212-2048
Teklenburg-Roord, S.T.A https://orcid.org/0009-0009-8464-4762
de Lorijn, F. https://orcid.org/0009-0001-8056-2657
Benninga, M.A. https://orcid.org/0000-0001-9406-9188
- License Information
-
More Information
Article History
Received: 6 February 2026
Revised: 23 April 2026
Accepted: 5 May 2026
First Online: 15 May 2026
Declarations
:
: Conflicts of interests: Marc A. Benninga is consultant for Mallinckrodt, Shire, Danone, FrieslandCampina, HIPP, Norgine, Abbott, Allergan, Coloplast, United Pharmaceuticals, Sensus, Cosun, and Wellspect. All honoraria were paid to the hospital (Amsterdam UMC). Arine M. Vlieger received research funding from Danone, paid to the hospital (St. Antonius Hospital). Ilan J.N. Koppen received research funding from Wellspect Healthcare and The EuroQol Research Foundation. These COIs are not directly related to the content of the current manuscript. All other authors declare no conflict of interest.
